PARP Inhibitors: Assessing the Clinical Trial Landscape

This educational series is supported by independent educational grants from AstraZeneca and Merck. CME Available: https://auau.auanet.org/node/31223 Course Description: PARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based, live virtual courses, featuring a unique topic related to PARP Inhibitors. For each session, a Moderator will engage two other subject matter experts in an interactive, interview-style presentation and discussion. Based on the documented need from the 2019 AUA global needs assessment in advanced prostate cancer, the AUA has produced a new series of educational offerings for the urologic care team focused on PARP inhibitors (PARPi). The first of three in the series PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape will address the latest developments in PARPi treatments and advanced prostate cancer care. Upon completion of this activity, participants will be able to: 1. Describe the role of the enzyme poly ADP ribose polymerase (PARP) in carcinogenesis as well as the mechanism of PARP inhibition. 2. Discuss the current clinical trials associated with PARP inhibitors. 3. Describe the patient populations associated with each trial. 4. State the clinical outcomes for each trial.